Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes

• Published in: Journal of allergy and clinical immunology Vol. 131; no. 2; pp. 461 - 467.e5
• Main Authors: Roufosse, Florence E., Kahn, Jean-Emmanuel, Gleich, Gerald J., Schwartz, Lawrence B., Singh, Anish D., Rosenwasser, Lanny J., Denburg, Judah A., Ring, Johannes, Rothenberg, Marc E., Sheikh, Javed, Haig, Ann E., Mallett, Stephen A., Templeton, Deborah N., Ortega, Hector G., Klion, Amy D.
• Format: Journal Article
• Language: English
• Published: New York, NY Mosby, Inc 01.02.2013; Elsevier; Elsevier Limited
• Subjects: Adolescent; adrenal cortex hormones; Adrenal Cortex Hormones - adverse effects; Adrenal Cortex Hormones - therapeutic use; Adult; Aged; Allergy and Immunology; Antibodies; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - immunology; Antibodies, Monoclonal, Humanized - therapeutic use; average daily intake; Biological and medical sciences; Blood; Cancer; Clinical trials; Corticoids; corticosteroid; death; Double-Blind Method; Drug dosages; Eosinophil; Eosinophilia; Eosinophilia - drug therapy; Eosinophilia - immunology; Female; Fundamental and applied biological sciences. Psychology; Fundamental immunology; Hematologic and hematopoietic diseases; Humans; Hypereosinophilic Syndrome - drug therapy; Hypereosinophilic Syndrome - immunology; Immunopathology; interleukin-5; Laboratories; Leukocytes (eosinophilic); Male; Medical sciences; Medical treatment; Middle Aged; Monoclonal antibodies; monoclonal antibody; neutralizing antibodies; Other diseases. Hematologic involvement in other diseases; Pain; patients; Population; Prednisone; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis; therapeutics; Time; Toxicity; Young Adult; L-HES; AE; SAE; HES; corticosteroid; SEER; monoclonal antibody; Eosinophil; AITL; interleukin-5; AEC; Absolute eosinophil count; Angioimmunoblastic T cell lymphoma; Hypereosinophilic syndromes; Adverse event; Lymphocytic variant HES; Surveillance Epidemiology and End Results; Serious adverse event; Corticosteroid; Immunopathology; Toxicity; Cytokine; Granulocyte; Hemopathy; Monoclonal antibody; Long term; Mepolizumab; Immunology; Interleukin 5; Treatment; Hypereosinophilic syndrome

Hypereosinophilic syndromes (HESs) are chronic disorders that require long-term therapy to suppress eosinophilia and clinical manifestations. Corticosteroids are usually effective, yet many patients become corticosteroid refractory or develop corticosteroid toxicity. Mepolizumab, a humanized monoclo...